New research from the Oregon Health & Science University Cancer Institute about mutations in melanoma may bring a wellspring of hope to many patients.Researchers have discovered that there are several different kinds of DNA abnormalities that can occur in a gene called the KIT gene. These abnormalities are associated with different kinds of acral and mucosal melanomas, which are less common, but highly malignant forms of skin cancer.

This post is an original post by ScienceDaily: Skin Care News

Posted: May 30th, 2008 under skin health.
Comments: none

In Germany alone, about three million - mostly elderly - patients suffer from poorly healing large-area wounds caused by complaints such as diabetes, burns or bedsores. The wounds can be treated with conventional collagen dressings or polylactic acid dressings, but the success rate is not as good as it should be. A new type of dressing made of silica gel fibers, developed by scientists at the Fraunhofer Institute for Silicate Research ISC in Würzburg, shall solve the problem.

This post is an original post by ScienceDaily: Skin Care News

Posted: May 30th, 2008 under skin health.
Comments: none

Researchers have expressed concern over a new campaign initiated by the tanning industry, which seeks to dispel the link between melanoma, the most serious form of skin cancer, and UV exposure from natural or artificial sources (such as tanning beds). In response, nearly 500 of the foremost experts on melanoma signed a statement affirming the existence of evidence-based data demonstrating the harmful effects of UVA and UVB radiation.

This post is an original post by ScienceDaily: Skin Care News

Posted: May 30th, 2008 under skin health.
Comments: none

Provectus Pharmaceuticals, Inc. (OTC BB: PVCT) has begun Phase 2 clinical testing of PH-10, the company’s topical drug for dermatology, for the treatment of atopic dermatitis, a chronic skin condition that includes some forms of eczema. The study is designed to evaluate efficacy of PH-10 in a total of twenty subjects with mild to severe forms of the disease. In the study, subjects will apply PH-10 daily for up to four weeks to their skin areas affected by atopic dermatitis.

This post is an original post by ScienceDaily: Skin Care News

Posted: May 30th, 2008 under skin health.
Comments: none

UK consumer watchdog Which? published research today that shows some top brand sunscreens don’t offer the level of protection they claim on the label.Which? tested 14 brands that claimed to have a sun protection factor (SPF) of 15 and three of them failed the test twice. To pass the test the sunscreens had to produce an average SPF of 12.5, the industry standard.

This post is an original post by ScienceDaily: Skin Care News

Posted: May 29th, 2008 under skin health.
Comments: none

A new type of wound dressing made of silica gel fibers will soon help to heal difficult wounds caused by burns or diabetes. The dressing forms a supporting matrix for newly growing skin cells and is fully absorbed by the body during the healing process.

This post is an original post by ScienceDaily: Skin Care News

Posted: May 29th, 2008 under skin health.
Comments: none

A review of data based on ten years of experience using efalizumab (Raptiva®) to treat chronic plaque psoriasis confirms that that the drug has a favorable long-term safety profile. The chronic plaque form of psoriasis accounts for about 75 percent of psoriasis cases.

This post is an original post by ScienceDaily: Skin Care News

Posted: May 28th, 2008 under skin health.
Comments: none

A review of data based on ten years of experience using efalizumab (Raptiva®) to treat chronic plaque psoriasis confirms that that the drug has a favorable long-term safety profile. The chronic plaque form of psoriasis accounts for about 75 percent of psoriasis cases.

This post is an original post by ScienceDaily: Skin Care News

Posted: May 28th, 2008 under skin health.
Comments: none

Dozens of studies show collagen repair is possible and demonstrate why three types of available skin treatments are effective: topical retinoic acid, carbon dioxide laser resurfacing and injections of cross-linked hyaluronic acid.

This post is an original post by ScienceDaily: Skin Care News

Posted: May 28th, 2008 under skin health.
Comments: none

Arpida Ltd (SWX: ARPN) announced the enrolment of the first patients into the Phase II “intravenous-to-oral” switch trial with oral iclaprim in complicated Skin and Skin Structure Infections (cSSSI). Enrolment remains on track for completion in 2008. The key objective of the study is to assess the clinical efficacy of an oral capsule formulation of iclaprim as step-down therapy in comparison with a full course of intravenous (i.v.

This post is an original post by ScienceDaily: Skin Care News

Posted: May 27th, 2008 under skin health.
Comments: none